People · Operator
Named in public records as an officer, director or promoter · active 2010–2012 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Smisson-Cartledge Biomedical, LLC | — | Biotechnology | Seed | $3.4M | $88.8M | 2010 |
Calder B. Clay III at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Calder B. Clay III on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ted B. Graham | 1 | 1 |
| Richard G. Cartledge, M.D. | 1 | 1 |
| Thomas W. Glasgow, Jr. | 1 | 1 |
| Steve W. Zenczak | 1 | 1 |
| Hugh F. Smisson III, M.D. | 1 | 1 |
| David C. Field | 1 | 1 |
| Christopher T. Collins | 1 | 1 |
| Steve T. Zenezak | 1 | 1 |
| Steve T. Zenczak | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.